Headlines about Rhythm Pharmaceuticals (NASDAQ:RYTM) have trended somewhat positive this week, according to Accern Sentiment Analysis. The research group rates the sentiment of news coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Rhythm Pharmaceuticals earned a news impact score of 0.09 on Accern’s scale. Accern also gave media coverage about the company an impact score of 47.5608338226028 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
Rhythm Pharmaceuticals (NASDAQ RYTM) opened at $26.35 on Friday. Rhythm Pharmaceuticals has a 12 month low of $21.38 and a 12 month high of $33.81.
Rhythm Pharmaceuticals (NASDAQ:RYTM) last issued its quarterly earnings results on Tuesday, November 14th. The company reported ($1.78) EPS for the quarter, missing the consensus estimate of ($0.40) by ($1.38). equities research analysts expect that Rhythm Pharmaceuticals will post -1.63 earnings per share for the current fiscal year.
ILLEGAL ACTIVITY WARNING: “Rhythm Pharmaceuticals (RYTM) Receives Daily Coverage Optimism Rating of 0.09” was first published by BBNS and is the sole property of of BBNS. If you are viewing this story on another publication, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this story can be viewed at https://baseballnewssource.com/markets/rhythm-pharmaceuticals-rytm-receives-daily-coverage-optimism-rating-of-0-09/1886567.html.
About Rhythm Pharmaceuticals
Rhythm Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of peptide therapeutics for the treatment of rare genetic deficiencies that result in life-threatening metabolic disorders. The Company’s lead peptide product candidate is setmelanotide, a potent, first-in-class melanocortin-4 receptor, or MC4R, agonist for the treatment of rare genetic disorders of obesity.
Receive News & Ratings for Rhythm Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rhythm Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.